相关实验视频
Updated: Jan 14, 2026

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.0K
帕金森病超出大脑范围:对治疗方法的影响
Setareh Malekian Naeini1, Marc Danzell Lopez2, Paul E Fraser2,3
1Department of Physiology, University of Toronto, Toronto, ON, Canada.
Frontiers in aging neuroscience
|October 27, 2025
概括
帕金森病 (PD) 可能从肠道开始,神经系统的α-synuclein病理与早期症状有关. 研究探讨了肠道微生物组的变化,炎症和α-synuclein传播,提出了新的诊断和治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
背景情况:
- 周边神经元中的α-synuclein病理与"身体第一"帕金森病 (PD) 的早期非运动症状相关.
- 肠道神经系统被认为是PD的潜在发病地点,受环境,遗传,免疫和年龄相关因素的影响.
研究的目的:
- 审查肠道微生物组和肠道透性在驱动PD系统性炎症和神经退行症中的作用.
- 探索α-synuclein聚合物的形成,传播和PD的潜在治疗策略.
主要方法:
- 综合分子生物学和临床研究成果的文献综述.
- 探索参与α-synuclein聚合和传播的途径.
- 突出了PD系统性基因疗法的进展.
主要成果:
- 肠道微生物组的改变和肠道透性的增加可能会在PD中发生神经退行.
- 阿尔法同核素聚合物可以通过神经元传播,有助于大脑病理.
- 系统性基因疗法具有针对多个受PD影响的器官的潜力.
结论:
- 肠-大脑轴在帕金森病的多因素病因学中发挥着关键作用.
- 了解这些相互关联的途径可能会导致PD的新型诊断和治疗干预措施.
相关概念视频
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Brainstem
5.7K
The brainstem, located inferior to the brain and superior to the spinal cord, serves as a bridge between the cerebrum and the spinal cord. It plays a vital role in relaying information and controlling critical life functions. It comprises three primary regions: the midbrain, pons, and medulla oblongata.
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
The Midbrain
The midbrain is located beneath the diencephalon and connects the cerebrum with the lower parts of the brain. The cerebral peduncles are prominent midbrain structures that house the...
5.7K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K

